Fostamatinib As Second-Line Itp Therapy

Fostamatinib as Second-Line ITP Therapy

Second-Line Treatment Options for Patients with ITP

Investigating the Use of Fostamatinib in ITP

ITP: Second-Line Therapy

Targeted Oncology

Fostamatinib and efgartigimod: novel agents in the treatment of ITP

VJHemOnc – Video Journal of Hematology & HemOnc

ITP: When to Switch to Second-Line Therapy

Targeted Oncology

Treating Persistent/Chronic ITP Current Care, Future Potential

ISTH

Dr. Fertrin on the Potential of Fostamatinib in Chronic ITP

Second-Line Therapy and Beyond for ITP

Targeted Oncology

Immune Thrombocytopenia | Oncology Today with Dr Neil Love: Management of Immune Thrombocytopenia...

Research To Practice

Immune Thrombocytopenia (ITP): Advances in Treatment in 2020

Immunosuppressive Therapy in ITP

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

First-Line Therapy Options for Patients with ITP

Treatment of Steroid-Refractory Immune Thrombocytopenia

Mayo Proceedings

Novel investigational drugs and promising therapies for immune thrombocytopenia

VJHemOnc – Video Journal of Hematology & HemOnc

ITP Treatment Selection Criteria and Treatment Goals

Modern Management of ITP: Thinking Beyond the Conventional Therapies

Impact of Therapy Choice on Fatigue in Adults with Immune Thrombocytopenia

Platelet Disorder Support Association

What’s new in ITP Treatment Presentation by Dr Drew Provan

ITP Support Association